Clinical Trial Update: Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC). [Phase 3]

View source ↗

Summary

A Phase 3 real-world study is ongoing to evaluate Vesemnogene Lantuparvovec for spinal muscular atrophy in low- and middle-income countries. Recruitment is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Vesemnogene Lantuparvovec

Snippet

Sponsor: Lantu Biopharma | Conditions: Spinal Muscular Atrophy (SMA) | Phase 3 | Status: RECRUITING